Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
复制标题
DOI:
10.1186/s13075-015-0644-z
复制
发表时间:
2015-05-18
影响因子:
4.9
通讯作者:
Whiting CC
中科院分区:
文献类型:
--
作者:
Nair N;Mei HE;Chen SY;Hale M;Nolan GP;Maecker HT;Genovese M;Fathman CG;Whiting CC
The development of biomarkers for autoimmune diseases has been hampered by a lack of understanding of disease etiopathogenesis and of the mechanisms underlying the induction and maintenance of inflammation, which involves complex activation dynamics of diverse cell types. The heterogeneous nature and suboptimal clinical response to treatment observed in many autoimmune syndromes highlight the need to develop improved strategies to predict patient outcome to therapy and personalize patient care. Mass cytometry, using CyTOF®, is an advanced technology that facilitates multiparametric, phenotypic analysis of immune cells at single-cell resolution. In this review, we outline the capabilities of mass cytometry and illustrate the potential of this technology to enhance the discovery of cellular biomarkers for rheumatoid arthritis, a prototypical autoimmune disease.
登录
查看更多内容
影响因子:
16.8
作者:
Bendall SC;Nolan GP;Roederer M;Chattopadhyay PK
通讯作者:
Chattopadhyay PK
影响因子:
4.6
作者:
Burska AN;Hunt L;Boissinot M;Strollo R;Ryan BJ;Vital E;Nissim A;Winyard PG;Emery P;Ponchel F
通讯作者:
Ponchel F
影响因子:
2.5
作者:
Chen, Lujun;Lu, Yahua;Wang, Fengming
通讯作者:
Wang, Fengming
DOI:
10.1126/science.1198704
发表时间:
2011-05-06
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Bendall SC;Simonds EF;Qiu P;Amir el-AD;Krutzik PO;Finck R;Bruggner RV;Melamed R;Trejo A;Ornatsky OI;Balderas RS;Plevritis SK;Sachs K;Pe'er D;Tanner SD;Nolan GP
通讯作者:
Nolan GP
影响因子:
48
作者:
Aghaeepour N;Finak G;FlowCAP Consortium;DREAM Consortium;Hoos H;Mosmann TR;Brinkman R;Gottardo R;Scheuermann RH
通讯作者:
Scheuermann RH